Tina Tong

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine”.

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

New England Journal of Medicine(2021)10.1056/nejmoa2105290

N/A

7.5DataRank · unranked

684 citations

Magdalena E. Sobieszczyk, Ian Hirsch, Stephanie Sproule, Merlin L. Robb, Lawrence Corey +40 more

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Journal of Clinical Investigation(2022)10.1172/jci160565

N/A

1.1DataRank · unranked

33 citations

Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck +18 more

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(23)00263-1

N/A

0.750DataRank · unranked

24 citations

Nadine Rouphael, Stephen R. Walsh, Aiying Chen, Nicole Grunenberg, Mary Allen +95 more

Leveraging lessons learned from the COVID-19 pandemic for HIV

Communications Medicine(2022)10.1038/s43856-022-00175-8

N/A

0DataRank · unranked

5 citations

Tina Tong, Dale J. Hu, Jérôme H. Kim, Karen L. Kotloff, Richard A. Koup +7 more

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

npj Vaccines(2023)10.1038/s41541-023-00630-0

N/A

0DataRank · unranked

40 citations

Youyi Fong, Holly Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule +37 more